GoodRx Q2 Revenue Beats, Raises 2026 Outlook on Pharma Direct Surge
GDRX sits 94% above its 52-week low of $1.77.
Summary
GoodRx delivered a strong Q2, with revenue of $200.4M beating the $193.2M consensus and adjusted EBITDA of $63.7M topping estimates. The beat was driven by a 76% surge in Pharma Direct revenue and 39% growth in subscriptions, offsetting a 26% decline in prescription transactions. Management raised full-year 2026 revenue guidance to $790M-$805M and adjusted EBITDA to $240M-$250M, signaling confidence in the shift toward higher-margin pharma manufacturer relationships and subscription programs. This follows a Q1 marked by an 89% net income drop and core transaction weakness, making the pivot's traction a critical inflection point. The stock, trading at 10x forward earnings, may re-rate if the new revenue mix proves sustainable.
At the time of this announcement, GDRX was trading at $3.43 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.77 to $5.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.